Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

26.7%

4 terminated/withdrawn out of 15 trials

Success Rate

55.6%

-30.9% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

5(45.5%)

Phase 1

3(27.3%)

Phase 2

2(18.2%)

N/A

1(9.1%)

11Total

Phase 3(5)

Phase 1(3)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT03136445Phase 3Completed

TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

Role: lead

NCT03042143Phase 1Active Not Recruiting

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)

Role: collaborator

NCT06167928Recruiting

Developing Allogeneic Musculoskeletal Therapies

Role: collaborator

NCT04704869Phase 3Completed

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Role: collaborator

NCT05148806Completed

Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies

Role: collaborator

NCT02585622Phase 1Terminated

NEPHSTROM for Diabetic Kidney Disease

Role: collaborator

NCT05271929Phase 3Terminated

Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19

Role: collaborator

NCT02997878Phase 1Active Not Recruiting

Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH

Role: collaborator

NCT04021316Not ApplicableTerminated

Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration

Role: collaborator

NCT00512577Phase 3Terminated

Transfusion Alternatives Pre-operatively in Sickle Cell Disease (TAPS)

Role: lead

NCT01050881Completed

Notification of Donors With Positive Microbiology Markers

Role: lead

NCT03871244Phase 3Unknown

Pilot Optimizing Transfusion Thresholds in Critically-ill Children With Anaemia

Role: collaborator

NCT04954937Unknown

Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.

Role: lead

NCT01815632Phase 2Unknown

Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)

Role: collaborator

NCT02105532Phase 2Completed

Transfusion in Gastrointestinal Bleeding

Role: collaborator

All 15 trials loaded